A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer

EBioMedicine

Volumn 2, Issue 1, 2015, Pages 82-90

  Krishna, Sanjeev ^a   Ganapathi, Senthil ^b   Ster, Irina Chis ^a   Saeed, Mohamed E M ^c   Cowan, Matt ^d   Finlayson, Caroline ^a   Kovacsevics, Hajnalka ^a   Jansen, Herwig ^e   Kremsner, Peter G ^f   Efferth, Thomas ^c   Kumar, Devinder ^b  

^a Institute of Infection and Immunity   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d EAST SURREY HOSPITAL   (United Kingdom)

^e Dafra Pharma International   (Belgium)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Artesunate; Colorectal cancer; Dihydroartemisinin; Ki67; Neutropaenia

Indexed keywords

ARTESUNATE; CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MYC PROTEIN; PLACEBO; PROTEIN P53; TUMOR MARKER; VASCULOTROPIN; ARTEMISININ DERIVATIVE; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DATA PROCESSING; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMICOLECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IRON DEFICIENCY ANEMIA; LEUKOPENIA; MALE; NAUSEA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SURVIVAL; VERY ELDERLY; COLORECTAL NEOPLASMS; DEMOGRAPHY; METABOLISM; ORAL DRUG ADMINISTRATION; STAINING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ARTEMISININS; BIOMARKERS, TUMOR; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; PILOT PROJECTS; PLACEBOS; STAINING AND LABELING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84927757551     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2014.11.010     Document Type: Article

References (43)

1. Alcaide J., Funez R., Rueda A., et al. The role and prognostic value of apoptosis in colorectal carcinoma. BMC Clin. Pathol. 2013, 13(1):24.
2. Anfosso L., Efferth T., Albini A., Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J. 2006, 6(4):269-278.
3. Arain M., Campbell M.J., Cooper C.L., Lancaster G.A. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med. Res. Methodol. 2010, 10:67.
4. Bendardaf R., Ristamaki R., Kujari H., et al. Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology 2003, 64(4):435-442.
5. Berger T.G., Dieckmann D., Efferth T., et al. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol. Rep. 2005, 14(6):1599-1603.
6. Betge J., Pollheimer M.J., Lindtner R.A., et al. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 2012, 118(3):628-638.
7. Bethell D., Se Y., Lon C., et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin. Infect. Dis. 2010, 15:e105-e114.
8. Breuer E., Efferth T. Treatment of iron-loaded veterinary sarcoma by Artemisia annua. Nat. Prod. Bioprospect. 2014, 4:113-118.
9. Efferth T., Rucker G., Falkenberg M., et al. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 1996, 46(2):196-200.
10. Efferth T., Dunstan H., Sauerbrey A., Miyachi H., Chitambar C.R. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 2001, 18(4):767-773.
11. Efferth T., Sauerbrey A., Olbrich A., et al. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 2003, 64(2):382-394.
12. Efferth T., Ramirez T., Gebhart E., Halatsch M.E. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem. Pharmacol. 2004, 67(9):1689-1700.
13. Efferth T., Giaisi M., Merling A., Krammer P.H., Li-Weber M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2007, 2(8):e693.
14. Ericsson T., Blank A., von Hagens C., Ashton M., Abelo A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur. J. Clin. Pharmacol. 2014, 70:1453-1463.
15. Ferlay J., Soerjomataram I., Ervik M., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 2012, (accessed 11 July 2014).
16. Fiandalo M.V., Kyprianou N. Caspase control: protagonists of cancer cell apoptosis. Exp. Oncol. 2012, 34(3):165-175.
17. Ganapathi S., Kumar D., Katsoulas N., et al. Colorectal cancer in the young: trends, characteristics and outcome. Int. J. Color. Dis. 2011, 26(7):927-934.
18. Gomes M.F., Faiz M.A., Gyapong J.O., et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 2009, 373(9663):557-566.
19. Hien T.T., Arnold K., Vinh H., et al. Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 1992, 86:582-583.
20. Hien T.T., Arnold K., Hung N.G., et al. Single dose artemisinin-mefloquine treatment for acute uncomplicated malaria. Trans. R. Soc. Trop. Med. Hyg. 1994, 88:688-691.
21. Ikenaga M., Takano Y., Saegusa M., et al. Apoptosis of colon cancers assessed by in situ DNA nick end-labeling method. Pathol. Int. 1996, 46(1):33-37.
22. Jansen F.H., Adoubi I., Comoe J.C., et al. First study of oral artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. Anticancer Res. 2011, 31(12):4417-4422.
23. Jiang J.B., Li G.Q., Guo X.B., Kong Y.C., Arnold K. Antimalarial activity of mefloquine and qinghaosu. Lancet 1982, ii:285-288.
24. Konkimalla V.B., Efferth T. Inhibition of epidermal growth factor receptor over-expressing cancer cells by the aphorphine-type isoquinoline alkaloid, dicentrine. Biochem. Pharmacol. 2010, 79(8):1092-1099.
25. Konkimalla V.B., McCubrey J.A., Efferth T. The role of downstream signaling pathways of the epidermal growth factor receptor for artesunate's activity in cancer cells. Curr. Cancer Drug Targets 2009, 9(1):72-80.
26. Kremsner P.G., Krishna S. Antimalarial combinations. Lancet 2004, 364:285-294.
27. Kremsner P.G., Taylor T., Issifou S., et al. A simplified intravenous artesunate regimen for severe malaria. J. Infect. Dis. 2012, 205(2):312-319.
28. Krishna S., Bustamante L., Haynes R.K., Staines H.M. Artemisinins: their growing importance in medicine. Trends Pharmacol. Sci. 2008, 29(10):520-527.
29. Li L.N., Zhang H.D., Yuan S.J., Tian Z.Y., Wang L., Sun Z.X. Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int. J. Cancer 2007, 121(6):1360-1365.
30. Liang P., Nakada I., Hong J.W., et al. Prognostic significance of immunohistochemically detected blood and lymphatic vessel invasion in colorectal carcinoma: its impact on prognosis. Ann. Surg. Oncol. 2007, 14(2):470-477.
31. Nealon C., Dzeing A., Muller-Romer U., et al. Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob. Agents Chemother. 2002, 46(12):3933-3939.
32. Rolling T., Schmiedel S., Wichmann D., Wittkopf D., Burchard G.D., Cramer J.P. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar. J. 2012, 11:169.
33. Rolling T., Agbenyega T., Issifou S., et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria-a double-center prospective study. J. Infect. Dis. 2014, 209(12):1921-1928.
34. Rutteman G.R., Erich S.A., Mol J.A., et al. Safety and efficacy field study of artesunate for dogs with non-resectable tumours. Anticancer Res. 2013, 33(5):1819-1827.
35. Singh N.P., Panwar V.K. Case report of a pituitary macroadenoma treated with artemether. Integr. Cancer Ther. 2006, 5(4):391-394.
36. Singh N., Verma K. Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch. Oncol. 2002, 2002:279-280.
37. Talbot I.C., Ritchie S., Leighton M.H., Hughes A.O., Bussey H.J., Morson B.C. The clinical significance of invasion of veins by rectal cancer. Br. J. Surg. 1980, 67(6):439-442.
38. Team RDC R: A Language and Environment for Statistical Computing (accessed 12 July 2014). http://www.R-project.org/.
39. Thomas A., O' Hara R., Ligges U., Sturtz S. Making BUGS open. R News 2006, 6(1):12-17.
40. UK CR Bowel Cancer Statistics (accessed 11 July 2014). http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/.
41. Yamamoto T., Igarashi N., Kato Y., Kobayashi M., Kawakami M. Apoptosis in adenoma and early adenocarcinoma of the colon. Histol. Histopathol. 1998, 13(3):743-749.
42. Yeung T.M., Buskens C., Wang L.M., Mortensen N.J., Bodmer W.F. Myofibroblast activation in colorectal cancer lymph node metastases. Br. J. Cancer 2013, 108(10):2106-2115.
43. Zhang Z.Y., Yu S.Q., Miao L.Y., et al. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 2008, 6(2):134-138.